MX2021007780A - Composiciones y metodos para tratar trastornos neurodegenerativos. - Google Patents

Composiciones y metodos para tratar trastornos neurodegenerativos.

Info

Publication number
MX2021007780A
MX2021007780A MX2021007780A MX2021007780A MX2021007780A MX 2021007780 A MX2021007780 A MX 2021007780A MX 2021007780 A MX2021007780 A MX 2021007780A MX 2021007780 A MX2021007780 A MX 2021007780A MX 2021007780 A MX2021007780 A MX 2021007780A
Authority
MX
Mexico
Prior art keywords
compositions
pharmaceutically acceptable
methods
formula
acid compound
Prior art date
Application number
MX2021007780A
Other languages
English (en)
Inventor
Jinhwan Lee
Jae Bong Moon
Byoung Joo Gwag
Original Assignee
Gnt Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gnt Pharma Co Ltd filed Critical Gnt Pharma Co Ltd
Publication of MX2021007780A publication Critical patent/MX2021007780A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

La presente invención se refiere a composiciones farmacéuticas para tratar deterioro cognitivo en animales de compañía, que comprenden un compuesto de ácido 5-bencilaminosalicílico de fórmula (I), o una sal del mismo farmacéuticamente aceptable; y un excipiente farmacéuticamente aceptable, por ejemplo, adecuado para administración oral. Las composiciones que comprenden el compuesto de ácido 5-bencilaminosalicílico de fórmula (I), o una sal del mismo farmacéuticamente aceptable pueden ser usadas para tratar trastorno cognitivo progresivo en enfermedades neurológicas que incluyen síndrome de disfunción cognitiva (CDS), distimia, depresión involutiva, y síndrome confusional en animales de compañía envejecidos.
MX2021007780A 2018-12-28 2019-12-26 Composiciones y metodos para tratar trastornos neurodegenerativos. MX2021007780A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785903P 2018-12-28 2018-12-28
PCT/IB2019/001409 WO2020136441A1 (en) 2018-12-28 2019-12-26 Compositions and methods for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2021007780A true MX2021007780A (es) 2021-12-15

Family

ID=71121937

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007780A MX2021007780A (es) 2018-12-28 2019-12-26 Composiciones y metodos para tratar trastornos neurodegenerativos.

Country Status (11)

Country Link
US (2) US20200206172A1 (es)
EP (1) EP3902536A4 (es)
JP (1) JP2022515520A (es)
KR (1) KR20210107828A (es)
CN (1) CN113710242A (es)
AU (1) AU2019412533A1 (es)
BR (1) BR112021012707A2 (es)
CA (1) CA3124767A1 (es)
MX (1) MX2021007780A (es)
PH (1) PH12021551541A1 (es)
WO (1) WO2020136441A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102454371B1 (ko) * 2019-07-08 2022-10-14 주식회사 지엔티파마 5-벤질아미노살리실산 유도체를 포함하는 화장품 조성물 및 이의 국소 사용방법
CN113735726A (zh) * 2021-08-09 2021-12-03 浙江理工大学 一种2-羟基-5-[2-(4-(三氟甲基苯基)乙基氨基)]苯甲酸钠及其制备方法
US20230233503A1 (en) * 2021-12-28 2023-07-27 Gnt Pharma Co., Ltd. Compositions and methods for treating pulmonary disorders
CN114414332B (zh) * 2022-01-05 2024-04-16 北京科技大学 一种基于Al-CQDs和Al-CNSs的抗氧化剂的制备方法
KR102517992B1 (ko) 2022-05-26 2023-04-05 주식회사 에이엘 네트웍스 인지장애 및 뇌기능 개선을 위한 펫푸드 조성물 및 이의 제조 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196348B (it) * 1984-11-29 1988-11-16 Italfarmaco Spa Composti ad attivita'antiinfiammatoria
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
CN101041626B (zh) * 2002-06-19 2010-08-25 艾克尔制药公司 四氟苄基衍生物及含有其成分的药物组合物
KR100522187B1 (ko) * 2002-10-18 2005-10-18 주식회사 뉴로테크 중추신경계의 급성 및 만성적 손상에 기인한 신경세포의퇴화를 방지하기 위한 화합물, 조성물 및 방법
US20070298129A1 (en) * 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
KR101204108B1 (ko) * 2009-02-09 2012-11-22 주식회사 지엔티파마 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
JP2012522058A (ja) * 2009-03-31 2012-09-20 リガンド・ファーマシューティカルズ・インコーポレイテッド 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤
KR101646701B1 (ko) * 2009-12-29 2016-08-08 주식회사 지엔티파마 에틸아미노 벤조산 유도체의 치료 용도

Also Published As

Publication number Publication date
KR20210107828A (ko) 2021-09-01
AU2019412533A1 (en) 2021-07-15
US20200206172A1 (en) 2020-07-02
EP3902536A4 (en) 2022-09-28
CN113710242A (zh) 2021-11-26
EP3902536A1 (en) 2021-11-03
US20220241231A1 (en) 2022-08-04
CA3124767A1 (en) 2020-07-02
BR112021012707A2 (pt) 2021-09-08
WO2020136441A1 (en) 2020-07-02
JP2022515520A (ja) 2022-02-18
PH12021551541A1 (en) 2022-02-28

Similar Documents

Publication Publication Date Title
PH12021551541A1 (en) Compositions and methods for treating neurodegenerative disorders
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
EA202091512A1 (ru) Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
MX2021004431A (es) Procesos novedosos.
MX2020001218A (es) Inhibidores selectivos de inflamasoma nlrp3.
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA033113B1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2013012588A (es) Inhibidores de cinasa.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
SG10201907289VA (en) Monomethylfumarate prodrug compositions
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AR092104A1 (es) LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
TW201613606A (en) Therapeutic drug for chronic renal failure
WO2018160055A8 (en) Method for preventing or treating autism spectrum disorders by benzoic acid salt
BR112014007684A2 (pt) tratamento da rinite